Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7097701 | 0.84 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL7098736 | 0.73 | ALDH1A1 (0.41) | ALDH1A1CYP3A4HTT | |
| SCHEMBL7103398 | 0.68 | ALDH1A1 (0.41) | ALDH1A1HTT | |
| SCHEMBL18438489 | 0.68 | ALDH1A1 (0.62) | ALDH1A1 | |
| SCHEMBL7104848 | 0.61 | ADRA2A (0.33) | — | |
| SCHEMBL17595436 | 0.59 | ALDH1A1 (0.49) | ALDH1A1CYP3A4 | |
| SCHEMBL7147951 | 0.58 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL12808838 | 0.57 | ALDH1A1 (0.60) | ALDH1A1HTT | |
| SCHEMBL6863294 | 0.57 | LMNA (0.45) | ALDH1A1HTT | |
| SCHEMBL10560727 | 0.56 | CYP3A4 (0.69) | ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | ALDH1A1 263/4885CYP3A4 720/4885HTT 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.